PATIENT ALERT CARD

Naxat (Rivaroxaban)
Naxat 10mg
Naxat 15mg
Naxat 20mg

Patient Alert Card
Keep this card with you at all times.
Present this card to every physician or dentist prior to treatment.

What should I know about Naxat?

- Naxat thins the blood, which prevents you from getting dangerous blood clots
- Naxat must be taken exactly as prescribed by your doctor. To ensure optimal protection from blood clots, **never skip a dose**
- You must not stop taking Naxat without first talking to your doctor as your risk of blood clots may increase
- Tell your health care provider about any other medicines you are currently taking, took recently or intend to start taking, before you start rivaroxaban
- Tell your health care provider that you are taking rivaroxaban before any surgery or invasive procedure

When should I seek advice from my health care provider?

When taking a blood thinner such as rivaroxaban it is important to be aware of its possible side effects. Bleeding is the most common side effect. Do not start taking rivaroxaban if you know you are at risk of bleeding, without first discussing this with your doctor.
Tell your doctor straight away if you have any signs or symptoms of bleeding such as the following:

- pain
- swelling or discomfort
- headache, dizziness or weakness
- unusual bruising, nosebleeds, bleeding of gums, cuts that take a long time to stop bleeding.
- menstrual flow or vaginal bleeding that is heavier than normal
- blood in your urine which may be pink or brown, red or black stools
- coughing up blood, or vomiting blood or material that looks like coffee grounds

How to take Naxat

To ensure optimal protection, rivaroxaban:

- 10 mg can be taken with or without food
- 15 mg must be taken with food
- 20 mg must be taken with food

I am under anticoagulation treatment with rivaroxaban

Name

Address

Birth date

Weight

Blood type

Other medicines / conditions

08395

In case of emergency, please notify:

Doctor's name

Doctor's phone

Doctor's stamp

Please also notify:

Name

Phone

Relationship

Information for health care providers:
INR values should not be used as they are not a dependable measure of the anticoagulant activity of rivaroxaban.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can contribute to the monitoring of Naxat's safety by reporting any adverse effects you experience to the Malta Medicines Authority, using the ADR reporting form, which is available online at: http://www.medicinesauthority.gov.mt/adrportal, and sent by post or email to;

P: Pharmacovigilance Section at Post-Licensing Directorate, Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000

E: postlicensing.medicinesauthority@gov.mt

Alternatively, adverse effects reports may be submitted to Delorbis Pharmaceuticals Ltd using the following contact details:
Telephone: +357 97 77 35 71
E-mail: drugsafety@delorbispharma.eu

By reporting side effects, you can help provide more information on the safety of this medicine.

NAXAT/PAC/v1.0-EN Approval date: 10/2026